CA-ARIBIO
5.1.2023 13:10:39 CET | Business Wire | Press release
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form F-4 in Connection With Proposed Business Combination7.4.2026 13:12:00 CEST | Press release
IQM Finland Oy, a global leader in deployed on-premises, full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp., a special purpose acquisition company (Nasdaq: RAAQ) (“RAAQ”), today announced the confidential submission of the draft registration statement on Form F-4 (the “Registration Statement”) filed by IQM with the U.S. Securities and Exchange Commission (“SEC”) relating to their proposed business combination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407372076/en/ IQM Quantum Computers The submission of the Registration Statement marks an important milestone toward the completion of the proposed business combination, which will result in IQM becoming a publicly traded company. The business combination remains subject to approval by RAAQ shareholders, the Registration Statement being declared effective by the SEC, and other customary closin
Reckitt Accelerates Innovation with NIQ AI Insights, reporting up to 65% faster research7.4.2026 12:30:00 CEST | Press release
Case study shows faster development and stronger-performing concepts NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new results from Reckitt’s use of NIQ BASES AI Screener, demonstrating how AI-powered insights and synthetic data are transforming innovation speed and effectiveness. The case study highlights how Reckitt has accelerated concept development while improving performance outcomes—bringing more relevant products to market, faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407069246/en/ NIQ BASES AI Screener As companies face growing pressure to innovate quickly in an increasingly complex consumer landscape, traditional research and development cycles can slow decision-making. Reckitt’s adoption of AI-powered screening reflects a broader shift toward predictive, data-driven innovation—where teams can test, refine, and optimize ideas before investing in physical development. Key Resul
Lincotek Appoints New Global General Manager for Its Medical Division7.4.2026 10:08:00 CEST | Press release
Gianluca Fioravanti to lead business as it enhances its offer to OEMs Lincotek today announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division - a global solution provider for the orthopedic market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407710572/en/ Gianluca Fioravanti, Global GM Lincotek’s Medical Division Reporting directly to Group CEO Andrea Colombo, Fioravanti assumed the role as of April 7 and will help drive the business forward. He will lead the development and execution of the company’s global growth strategy, while ensuring its seamless operational implementation across all regions. This strategic appointment reflects Lincotek’s commitment to enhance the value it delivers to customers, strengthening its ability to serve them better. Fioravanti brings more than 25 years of international experience to the Group, having held senior leadership roles across operation
Budweiser Honors 40 Years of FIFA World Cup™ Legacy with Limited-Edition Collectible Pack and Nostalgia-Themed Platform7.4.2026 09:00:00 CEST | Press release
The iconic brand marks its return as the Official Beer Sponsor of FIFA World Cup™ with anniversary packaging, a global film, and creative billboard tributes to football’s greatest moments Today, Budweiser is celebrating 40 years as the Official Beer Sponsor of the FIFA World Cup™ with the launch of the largest limited-edition collectible pack ever – the Budweiser® FIFA World Cup™ Anniversary Pack* – bringing to life 11 bold design tributes to every tournament since 1986, and the centerpiece of a new nostalgia driven global platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407304059/en/ Budweiser® FIFA World Cup™ Anniversary Pack Throughout history, Budweiser has played an important role in some of football’s most unforgettable celebrations, from last-minute goals to trophy lifts seen around the world. These moments of “Budstalgia” [Budweiser + nostalgia] are the inspiration for the brand’s newest platform, brought
Toshiba’s Breakthrough Algorithm Harnesses Edge of Chaos to Dramatically Boost Performance of its Quantum‑Inspired Computer7.4.2026 09:00:00 CEST | Press release
~Approximately 100 times faster, will accelerate solutions for drug discovery, finance, and other complex problems~ Toshiba Corporation has developed a breakthrough algorithm that dramatically boosts the performance of the Simulated Bifurcation Machine (SBM), its proprietary quantum‑inspired combinatorial optimization computer. The new algorithm significantly improves the probability of obtaining an optimal solution or a known best solution within a limited number of trials—referred to as the success probability, a key benchmark for evaluating combinatorial optimization technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407918434/en/ Figure 1: Results demonstrating that the newly developed third‑generation SB algorithm can find the known best solution with nearly 100% probability at the edge of chaos for a fully connected 2,000‑spin Ising problem. The SBM is designed to solve large‑scale combinatorial optimizati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom